There is still a long way to go before we can safely say we have a safe and working COVID-19 vaccine, but the recent announcements from Pfizer and BionTech, and Moderna, regarding their mRNA-based vaccines, are definitely reasons for feeling positive. And it’s incredible to think that these vaccines have come so far in less than 12 months. For this week’s newsletter, we round up statements regarding Pfizer and BionTech’s vaccine. We also caught up with a vaccine expert at Seqirus to find out what we’ve learned from influenza pandemics over the years – and how these lessons can help us with COVID-19. 

Stephanie Sutton, Editor.

The Pfizer COVID-19 Vaccine
11/13/2020 | Stephanie Sutton
Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.
Preparing for the Next Pandemic
11/19/2020 | Stephanie Sutton
A look at the past, present, and future of vaccine production – and how COVID-19 changes the outlook.
Green Trials
11/14/2020 | Stephanie Sutton
Implementing green practices in clinical trials.
Allogenic Advance
11/18/2020 | James Strachan
A step closer to an off-the-shelf CAR T cell therapy.
Interested in AAV-based gene therapies?

Don’t miss our three-part educational webinar series with Cytiva that covers modern plasmid and AAV production for gene therapy applications. Find out more

Exploring COVID-19 interventions with Roquette

The Medicine Maker will be hosting a webinar exploring innovations within vaccine formulations. I would like to invite you to join us and Roquette as we discuss the range of vaccines that are coming to market to tackle COVID-19. Find out more and register today! Sign me up!

Smart Shipping Solutions For Cell Therapy Logistics

Our webinar with Cytiva on overcoming cell therapy logistics without the hazards of liquid nitrogen is now available to view on demand. Stream now

White Papers
Theory and Practice of Differential Scanning Calorimetry

Differential scanning calorimetry (DSC) is an analytical technique with a proven track record for biomolecular stability studies. The benefits and specifics of DSC are discussed. Read More.

Use of SEC in the Analysis of Plasmid DNA

In the biopharmaceutical industry, plasmid DNA is used as both a raw material and active ingredient in vaccines.  Read More.

Product Profile
Vcaps® Plus – an immediate release capsule in HPMC only, without gelling agents

Vcaps® Plus have an in-vivo performance bioequivalent to gelatin. They offer an excellent dissolution profile with pH independent performance, low moisture content and great machinability. Read more

Special Promotions
The Cell + Gene Curator - a newsletter focused on the science of cell and gene therapies

Connecting you to discoveries, innovation, and business updates from the cell and gene therapy community. Learn more and subscribe

Join the industry at E&L Europe Online this December!

Jam-packed with expert speakers and key industry personnel, this year's online event will provide you with everything you need to know about extractables and leachables; from regulations all the way through to carrying out E&L studies. Learn more

Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.

Find out more